Andere Sprachen Orthocell Limited

Aktien

Verzögert Australian S.E. Andere Börsenplätze 02:06:44 15.05.2024			% 5 Tage	% 1. Jan.
0,4 ^AUD	0,00 %		+8,11 %	-2,44 %

14.05.	Orthocells Dentalmembranprodukt Striate+ erreicht 98,6% Erfolgsrate in klinischer Studie nach der Markteinführung; Aktien steigen um 3%	MT
15.04.	Orthocell sichert sich AU$3 Millionen F&E-Steuernachlass für das Geschäftsjahr 2023; Aktien steigen um 3%	MT

Orthocell's Striate+ Dental Membrane Product Achieves 98.6% Success Rate in Post-Market Clinical Study; Shares Up 3%	14.05.
Orthocell Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 3%	15.04.
Orthocell Revenue Soars 19% to AU$1.61 Million in Q1	09.04.
Orthocell Completes First Stage of Remplir US Market Authorization Study	25.03.
Orthocell raising $3.5 million; adds heavy hitters to register	23.02.
Orthocell Limited Reports Earnings Results for the Half Year Ended December 31, 2023	23.02.
Orthocell Completes AU$3.5 Million Share Placement	22.02.
Orthocell Submits Regulatory Application for Remplir in Singapore	13.02.
Orthocell Limited Announces Resignation of Matthew Callahan from the Board	15.01.
Orthocell Limited Appoints Kim Beazley AC as an Independent Non-Executive Director	14.01.
Orthocell Completes Chair Transition Process	22.12.
Orthocell Limited Announces Changes to its Board	21.12.
Orthocell on the cusp of significant growth	01.11.
Orthocell Limited Provides Commercial Revenue Guidance for the Full Year 2023	24.10.23
Orthocell Limited Announces Board Changes	24.10.23
Orthocell Limited Announces Board Changes	22.09.23
Orthocell Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31.08.23
Orthocell Secures Over AU$3 Million R&D Tax Rebate	21.06.23
Orthocell thrilled to welcome John Van Der Wielen as chairman	29.05.23
Orthocell Appoints Nonexecutive Chair	29.05.23

Keine Ergebnisse zu dieser Suche